Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Isolated right ventricular acute myocardial infarction mimicking anterior infarction].

Annales de cardiologie et d'angeiologie·2019
Same author

[Coronary artery spasm revealed by an out-of-hospital cardiac arrest associated with a moyamoya disease. A case report of multimodality imaging].

Annales de cardiologie et d'angeiologie·2019
Same author

[Optimal duration of dual antiplatelet therapy after coronary stent placement or acute coronary syndrome. Is customisation possible?]

Annales de cardiologie et d'angeiologie·2019
Same author

Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: "OLTAT registry".

International journal of cardiology·2018
Same author

[Complicated transcatheter aortic-valve endocarditis with abscess and pseudoaneurysm: Value of the ECG-gated multidetector computed tomography angiography].

Annales de cardiologie et d'angeiologie·2017
Same author

Ilio-psoas hematoma in the intensive care unit: a multicentric study.

Annals of intensive care·2016

Related Experiment Video

Updated: May 15, 2026

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves
11:12

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves

Published on: October 18, 2013

Bioprosthetic valve replacement in the elderly

G Helft1, X Tabone, J L Georges

  • 1Clinique Cardiologique, l'Hôpital Necker, Paris, France.

European Heart Journal
|April 1, 1995
PubMed
Summary

Bioprosthetic valve replacement in patients over 65 shows good long-term survival. While valve deterioration is low, non-valve related mortality is significant, emphasizing comprehensive patient care.

More Related Videos

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

Related Experiment Videos

Last Updated: May 15, 2026

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves
11:12

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves

Published on: October 18, 2013

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Biomedical Engineering

Background:

  • Bioprosthetic heart valves are widely used for valve replacement surgery.
  • Long-term outcomes in elderly patients undergoing these procedures require ongoing evaluation.

Purpose of the Study:

  • To assess the mid-term efficacy and safety of bioprosthetic valve replacement in patients older than 65 years.
  • To evaluate valve-related complications, reoperation rates, and overall survival.

Main Methods:

  • Retrospective analysis of 110 patients (mean age 73.4 years) who underwent bioprosthetic valve replacement (aortic, mitral, or both) between 1979 and 1985.
  • Follow-up averaged 75 months, with actuarial survival rates calculated.
  • Valve-related complications, reoperations, and mortality causes were documented.

Main Results:

  • Actuarial survival was 79.4% at 5 years and 55.2% at 10 years.
  • Low rates of primary structural deterioration (0.9%/patient-year) and reoperation mortality (12.5%) were observed.
  • Non-valve related mortality accounted for 51.4% of deaths; severe bleeding occurred in 5.4% of patients on anticoagulants.

Conclusions:

  • Bioprosthetic valve replacement in elderly patients offers favorable mid-term survival with a low incidence of structural deterioration.
  • Mortality is predominantly driven by non-valve related causes, highlighting the importance of managing comorbidities in this population.